News >

PSMA-Targeted Radionuclide Therapy Shows Preliminary Activity in mCRPC

Caroline Seymour
Published: Friday, Apr 10, 2020

Scott T. Tagawa, MD, MS, Richard A. Stratton Associate Professor in Hematology and Oncology

Scott T. Tagawa, MD, MS

The prostate-specific membrane antigen (PSMA)-targeted alpha-emitter 225actinium (225Ac) and radiolabeled monoclonal antibody J591 (225Ac-J591) showed encouraging preliminary safety and efficacy in men with pretreated, metastatic castration-resistant prostate cancer (mCRPC), according to findings from a phase I dose-escalation study (NCT03276572).
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication